A Company Built on Addiction Files for Bankruptcy — and Walks Away

From Painkiller Profits to Chapter 11

Endo International plc is an Irish-domiciled pharmaceutical company that, through its U.S. subsidiaries Endo Health Solutions Inc. and Endo Pharmaceuticals Inc., manufactured and marketed opioid products across the United States and Canada. By the time the company filed for Chapter 11 bankruptcy protection in 2022, it faced a staggering array of legal claims: state governments, cities, counties, tribal nations, hospitals, public school districts, third-party insurers, individual patients, and the babies of opioid-dependent mothers had all lined up to hold Endo accountable.

The plan filed in January 2024 lists no fewer than 16 separate classes of claimants, from “PI Opioid Claims” representing injured individuals to “NAS PI Claims” representing children born with Neonatal Abstinence Syndrome to “Public School District Claims” and “Canadian Provinces Claims.” Every single one of these groups represents a community or a body that alleges Endo’s conduct caused real, documented harm.

The plan does not dispute that the harm occurred. Its entire structure is built around the premise that the harm is real, quantifiable, and massive. Instead, the plan’s purpose is to resolve all of that harm through a complex series of trusts, each funded at a fraction of what the claims are actually worth, while the company’s assets transfer to a restructured new entity that emerges clean of liability.

The $4.5 Trillion Number Nobody Is Talking About

Buried in the definitions section of the bankruptcy plan is one of the most revealing sentences in modern corporate legal history. The document formally defines the “Deemed Opioid Claims Pool” as exactly $4.5 trillion ($4,500,000,000,000; a figure that dwarfs the annual federal budget and could fund the entire U.S. public school system for over 60 years). This is the number the parties agreed to use as a legal placeholder representing the total universe of opioid claims against Endo.

This number was not invented out of thin air. It reflects the collective, agreed-upon magnitude of the damage Endo’s opioid products caused. Yet the actual funds being distributed to opioid victims through the plan represent a fraction of a fraction of that figure. The gap between $4.5 trillion and the amounts actually reaching victims is the clearest possible evidence of what corporate bankruptcy law does in practice: it protects the company’s assets and creditors while rationing justice to the people who were hurt.

Exit Financing: Wall Street Gets Paid First

While victims receive settlements measured in thousands, the restructured entity emerging from Endo’s bankruptcy inherits up to $2.5 billion ($2,500,000,000; roughly equivalent to what 625,000 average American workers earn in a year combined) in exit financing. This is new debt the successor company takes on to fund its operations going forward. The first-lien creditors, primarily institutional investors and Wall Street funds, receive the bulk of the reorganized company’s equity through a rights offering process.

The First Lien ERO Enterprise Value, the agreed-upon value of the reorganized company’s equity, is set at $3.275 billion ($3,275,000,000; more than enough to fully fund the National Opioid Settlement programs for every state in the country). The First Lien Rights Offering amount alone totals $340 million. These are not small numbers, and they demonstrate that there is real value in this enterprise even after bankruptcy. That value flows to secured creditors and institutional investors; it does not flow to the people harmed by Endo’s products.

The Human Cost They Can’t Put a Number On

The NAS Children: Born Into a Crisis They Did Not Choose

Neonatal Abstinence Syndrome, or NAS, is what happens to a baby whose mother was dependent on opioids during pregnancy. The infant is born addicted. The symptoms include uncontrollable tremors, inconsolable crying, seizures, feeding difficulties, and severe withdrawal that can last weeks or months. These are not hypothetical injuries. These are documented medical conditions affecting tens of thousands of infants born in the United States each year at the peak of the opioid epidemic, and Endo’s own bankruptcy plan formally acknowledges their existence by creating a special class just for them: “NAS PI Claims.”

The plan even establishes an “Ad Hoc Committee of NAS Children,” a group of parents and guardians advocating on behalf of children born with NAS, formally registered in the bankruptcy case. These parents showed up. They organized. They filed verified statements with the bankruptcy court. The plan’s response to their organized advocacy is a Future NAS PI Trust funded at a share of $11.385 million ($11,385,000; roughly the cost of a single luxury penthouse apartment in New York City), split among all future claimants including both NAS babies and adult opioid injury survivors.

The plan also defines “Future NAS PI Claims” with a strict temporal cutoff: only children born after the General Bar Date of July 7, 2023, but before approximately 10 months after that date, qualify for this fund. Children born before that date, children who were already born and already suffering, must compete with other opioid claimants in separate trust pools. The corporate legal system has assigned a birth window to the value of a damaged childhood.

The Mesh Victims: A Second Crisis, Also Priced Into the Discount Bin

Endo’s liability does not begin and end with opioids. The company also manufactured and sold transvaginal mesh products, surgical implants that caused devastating internal injuries in tens of thousands of women. The plan creates a separate “Mesh Claims Trust” for these survivors and a “Future Mesh Trust” for women whose injuries from mesh implantation manifest in the future. The Future Mesh Trust is funded at a maximum of $495,000 ($495,000; roughly the median price of a single-family home in the United States), to be shared among all future mesh claimants.

Half a million dollars for a class of women who suffered chronic pelvic pain, organ perforation, recurring infections, and permanent nerve damage. Women who underwent multiple corrective surgeries. Women who lost their ability to work, to have sex without pain, to live without daily agony. Endo implanted their devices, collected the revenue, and then negotiated their futures into a trust smaller than the cost of a single upper-middle-class house.

The Communities Left to Absorb the Damage

Public school districts across the United States filed their own class of claims in this bankruptcy, a formal acknowledgment that the opioid crisis devastated educational communities. Schools absorbed children orphaned by overdoses. Schools trained staff to administer naloxone. Schools established programs for children with developmental delays linked to prenatal opioid exposure. Schools hired social workers and counselors to respond to family instability caused by addiction. The plan designates these as “Class 8 – Public School District Claims,” channeled into the Opioid School District Recovery Trust.

Tribal nations across the United States also filed claims, recognized in the plan as “Tribal Opioid Claims.” Indigenous communities experienced some of the highest per-capita rates of opioid addiction and overdose death in the country. The plan creates a “Tribal Opioid Trust” to address these claims. Canadian provinces, Canadian First Nations, and Canadian municipalities also bring claims, acknowledging that Endo’s marketing and distribution extended across North America and that the damage followed the pills wherever they went.

Hospitals filed as a separate class of claimants, the “Ad Hoc Group of Hospitals,” because emergency departments, detoxification units, neonatal ICUs, and addiction treatment programs bore enormous unreimbursed costs absorbing the medical consequences of opioid addiction. Third-party payers, insurance companies and health plans that paid for opioid prescriptions their patients did not need and could not safely use, also filed claims. The circle of documented harm in this bankruptcy is essentially the entirety of American civil society. Endo sold pills into a system that buckled under their weight, and the plan asks every part of that buckled system to accept a fraction of what it lost.

The Dignity of Being a Line Item

What the Non-Financial Ledger cannot fully capture is the indignity of this process itself. A mother whose child was born shaking and screaming in opioid withdrawal must now navigate a trust distribution process, file documentation, meet deadlines, and wait for a check from a fund that the company’s lawyers negotiated down to the smallest defensible number. The grief, the medical debt, the lost wages, the shattered family structures: these do not appear on any balance sheet. They appear in the “Deemed Opioid Claims Pool” figure, in the $4.5 trillion that everyone in this case agreed represented the real scale of harm, and then they disappear when the actual distribution tables are drawn up.

Direct From the Documents: Endo’s Own Words

They Named the Number. They Wrote It Down.

“Deemed Opioid Claims Pool” means $4.5 trillion. — Endo International Second Amended Joint Chapter 11 Plan of Reorganization, Section 1.1.91

“Future Opioid PI/NAS PI Trust Share” means the funding provided to the Future PI Trust for Distributions to holders of Allowed Future Opioid PI Claims and Allowed Future NAS PI Claims, as applicable, which shall be funded by the Debtors and/or the Purchaser Entities, as applicable, in an aggregate amount of up to $11.385 million in Cash. — Section 1.1.187, defining the maximum total fund for future opioid personal injury and NAS baby victims

“Future Mesh Trust Share” means the funding provided to the Future PI Trust for Distributions to holders of Allowed Future Mesh Claims, which shall be funded by the Debtors and/or the Purchaser Entities, as applicable, in an aggregate amount of up to $495,000 in Cash. — Section 1.1.182, defining the maximum fund for women harmed by transvaginal mesh products in the future

“DOJ Criminal Claim” means Claim No. 3056, filed by the DOJ against Debtors Endo International plc, Endo Health Solutions Inc., and Endo Pharmaceuticals Inc. and the pending criminal investigation of the aforementioned Debtors by the DOJ, as such Claim may be amended, supplemented, or modified from time to time, together with any Claims that could be asserted with respect thereto. — Section 1.1.111, confirming that a live DOJ criminal investigation existed at the time of plan filing

“Exit Financing” means indebtedness in an amount up to $2.5 billion that will be incurred or deemed to be incurred, as applicable, by the Purchaser Obligors on the Effective Date. — Section 1.1.139, defining the financial runway handed to the restructured company’s new creditor-owners

“Canadian Provinces Consideration” means a minimum aggregate amount of $725,000 in Cash, which amount may be increased up to a maximum aggregate amount of $7.25 million in Cash depending on the number of Canadian Provinces that grant or are deemed to grant, as applicable, the Non-GUC Releases. — Section 1.1.43, setting the maximum total payment to all Canadian provincial governments for opioid harms: $7.25 million ($7,250,000; roughly the annual salary of three mid-level NFL players)

The Damage Mapped Across Society

Public Health: An Epidemic Priced Into Trust Funds

The structure of this bankruptcy plan is itself a public health document. Every trust category in the plan corresponds to a documented category of human health damage. The PI Opioid Claims trust covers individuals who were diagnosed with medical, physical, cognitive, or emotional conditions resulting from their own use of opioids. The NAS PI Claims trust covers children who were diagnosed with Neonatal Abstinence Syndrome after intrauterine exposure to opioids. The Hospital Claims trust covers medical institutions that provided unreimbursed care to opioid patients. The Third-Party Payer Claims trust covers insurers that paid for prescriptions that caused addiction. Every single one of these trusts is a census of harm.

The plan’s definition of “Future Opioid PI Claims” is particularly revealing from a public health standpoint. It covers people who suffered injury from opioid use that began prior to January 1, 2019, but whose injuries manifested later. This cutoff date acknowledges that the health consequences of opioid addiction are long-tail: addiction ruins lives for years and decades after the initial prescription. Endo’s products created a public health time bomb, and the plan formally recognizes that the fuse is still burning while simultaneously capping how much the company will pay for the ongoing explosion.

The existence of the Future PI Trust, designed to handle claimants not yet born or whose injuries have not yet manifested, is the clearest possible evidence that the public health crisis is ongoing. Endo’s legal team did not create this trust as an act of generosity. They created it because the courts required them to account for future harm. The trust acknowledges that people will continue suffering from Endo’s products for years to come. The $11.385 million ceiling on that suffering is the company’s answer to that ongoing reality.

Economic Inequality: Wall Street Whole, Victims in Line

The bankruptcy plan’s financial architecture reveals a stark economic hierarchy. At the top sit the First Lien Creditors, institutional investors and hedge funds holding secured debt, who receive the reorganized company’s equity, participate in a $340 million rights offering, and inherit a company valued at $3.275 billion. Below them sit unsecured creditors, including trade creditors and unsecured noteholders, who receive shares in the GUC Trust and participate in the restructured equity. Below them sit the opioid victims, the mesh victims, the school districts, and the tribal nations, who receive allocations in separate trusts funded at figures that range from millions to hundreds of thousands of dollars.

The Generics Price Fixing Claims Trust, which handles claims from companies and consumers harmed by Endo’s alleged price-fixing of generic drugs, receives $16 million ($16,000,000; roughly the cost of a single corporate jet). These are claims from businesses and institutions with legal resources to negotiate. Individual opioid patients, NAS babies, and mesh victims receive less. The economic logic of bankruptcy law awards recovery in inverse proportion to vulnerability: the more financial and legal power a creditor has, the better their treatment under the plan.

The Canadian provincial governments, which represent entire provincial healthcare systems that absorbed the costs of the opioid crisis, receive between $725,000 and $7.25 million total, shared among up to 13 provincial and territorial governments. Individual provinces would receive amounts measured in tens to hundreds of thousands of dollars for a public health catastrophe that cost their healthcare systems billions in treatment, emergency response, and long-term care. The plan’s treatment of Canadian governments illustrates how bankruptcy law treats even sovereign entities as just another class of creditor to be managed and minimized.

The Broad Liability Shield: Who Gets Protected and Who Doesn’t

The plan’s release provisions deserve special attention. The bankruptcy plan grants what it calls “Non-GUC Releases” and “GUC Releases” to a wide range of parties, including the Debtors’ current and former directors, officers, and employees. The plan defines specific groups called “Excluded Parties,” entities that do not receive releases, including McKinsey, Arnold & Porter, Practice Fusion, Publicis Health, and ZS Associates. These are the consultants and marketing firms that allegedly helped design and execute Endo’s opioid marketing strategies. Their exclusion from releases is an implicit acknowledgment that their conduct was so potentially culpable that even Endo’s restructuring team could not include them in the liability shield.

But Endo’s own current and former directors and officers, the executives who made the decisions, who approved the marketing strategies, who signed off on the products and the distribution channels, receive releases under the plan. The plan creates a category called “Excluded D&O Parties,” covering “Non-Continuing Directors and Excluded Former Officers,” but even these individuals receive some protections from certain categories of claims. The GUC Trust preserves litigation rights against some of these parties through what the plan calls “GUC Trust Litigation Claims,” but that litigation is channeled through a trust, not through the victims themselves.

What Endo’s Plan Says a Damaged Childhood Is Worth